Miguel Islas-Ohlmayer, MD
Hematology & Oncology · Edgewood, KYNPI 1295917425
Payments from drug & device makers
Across 594 payments — averaging $2638.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$471K
- Bristol Myers Squibb$222K
- Pfizer$136K
- Novartis$127K
- Incyte Corporation$125K
- Genentech, Inc.$124K
- plus $363K from 33 others
Across 5 payments — averaging $1837.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$6K
- Eli Lilly$2K
- Pharmacyclics LLC, An Abbvie Company$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 176 | $470,796 |
| Bristol Myers Squibb | 17 | $221,531 |
| Pfizer | 5 | $135,836 |
| Novartis | 21 | $126,788 |
| Incyte Corporation | 82 | $125,432 |
| Genentech, Inc. | 24 | $123,720 |
| Eli Lilly | 2 | $58,459 |
| E.r. Squibb & Sons, L.L.C. | 11 | $49,639 |
| Pharmacyclics LLC, An Abbvie Company | 41 | $44,381 |
| TG Therapeutics, Inc. | 28 | $43,822 |
| AstraZeneca | 3 | $34,495 |
| ADC Therapeutics America, Inc. | 9 | $27,779 |
| Morphosys AG | 21 | $25,875 |
| Rigel Pharmaceuticals, Inc. | 32 | $19,680 |
| AbbVie | 17 | $15,871 |
| Jazz Pharmaceuticals Inc. | 22 | $11,163 |
| Epizyme, Inc. | 9 | $9,750 |
| Syndax Pharmaceuticals, Inc. | 8 | $7,287 |
| Gilead | 10 | $6,911 |
| Sobi, Inc | 2 | $3,204 |
| CTI Biopharma Corp. | 1 | $1,725 |
| Janssen Scientific Affairs, LLC | 1 | $1,363 |
| Beigene, Ltd. | 1 | $525 |
| Hoffmann-la Roche Limited | 1 | $285 |
| Johnson & Johnson(2 entities) | 19 | $269 |
| Karyopharm Therapeutics Inc. | 2 | $217 |
| National Marrow Donor Program | 1 | $163 |
| Amgen | 9 | $150 |
| Sanofi-aventis U.S. LLC | 1 | $121 |
| Astellas Pharma US Inc | 4 | $72 |
| GSK | 2 | $41 |
| Sanofi | 2 | $40 |
| Aurobindo Pharma USA, Inc. | 2 | $37 |
| Genentech USA, Inc. | 3 | $34 |
| Verastem, Inc. | 1 | $21 |
| Eisai Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Puma Biotechnology, Inc. | 1 | $15 |
| Global Blood Therapeutics, Inc. | 1 | $11 |
How this compares
$1,567,536 in reported general payments places this provider in the 90th percentile of 143 hematology & oncology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Edgewood
- Daniel FloraEdgewood$935K
- Brooke HolbrookEdgewood$417K
- Colleen DarnellEdgewood$348K
- Muhammad RiazEdgewood$288K
- Ivan Bedoya-ApraezEdgewood$28K
- Joseph MalyLouisville$7M
- Firas BadinLexington$6.7M
- Laila AgrawalLouisville$6.3M
- Jaspreet GrewalLouisville$4.2M
- John VillanoLexington$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.